The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and disease progression by programmed death-ligand 1 expression in gastroesophageal adenocarcinoma: A post hoc analysis of the RATIONALE-305 trial.
 
Marcia Cruz-Correa
Employment - Pan American Center for Oncology Trials
Stock and Other Ownership Interests - Pan American Center for Oncology Trials
Research Funding - Abbvie (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); GENFIT (Inst); HUYA Bioscience International (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); VMO (Inst)
Patents, Royalties, Other Intellectual Property - Licencing agreement with Johns Hopkins University on technology.
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; CPPC; Hengrui Pharm; Hutchison MediPharma; Innovent Biologics; Junshi Pharmaceuticals; Keymed Biosience; Merck Serono; MSD; QiLu Pharmaceutical; Roche
 
Markus Moehler
Honoraria - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Idience; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier; Transcenta; Triptych Health Partners
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD; Nordic Group; SERVIER; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; BeiGene; ESMO; German Cancer Society; Merck Serono; MSD; Roche; Sanofi Pasteur
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Frederick Barnes
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Yaling Xu
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene Shanghai
 
Tao Sheng
Employment - BeiGene Beijing
Stock and Other Ownership Interests - BeiGene Beijing
 
Gisoo Barnes
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Timothy Victor
Employment - BeiGene
Consulting or Advisory Role - BeiGene